Cambridge, United Kingdom

Peter Blencowe

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Peter Blencowe

Introduction

Peter Blencowe is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development of heterocyclic compounds. His work is particularly focused on the treatment and prophylaxis of cancer, showcasing his commitment to advancing medical science.

Latest Patents

Peter Blencowe holds 1 patent for his invention titled "Heterocyclic compounds for use in the treatment of cancer." This patent relates to heterocyclic amide derivatives and their application in cancer treatment. The invention also includes compositions containing these derivatives and outlines processes for their preparation, highlighting the potential impact on cancer therapies.

Career Highlights

Peter is currently associated with Artios Pharma Limited, a company dedicated to developing innovative cancer therapies. His role at Artios Pharma allows him to collaborate with other experts in the field and contribute to groundbreaking research that aims to improve patient outcomes.

Collaborations

Throughout his career, Peter has worked alongside talented individuals such as Mark Charles and Tennyson Ekwuru. These collaborations have fostered a dynamic environment for innovation and have played a crucial role in the advancement of their shared goals in cancer research.

Conclusion

Peter Blencowe's contributions to the field of cancer treatment through his innovative patents and collaborations exemplify the importance of research and development in medicine. His work continues to inspire advancements that may lead to more effective cancer therapies in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…